These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

500 related items for PubMed ID: 15302800

  • 1. Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein: a randomized placebo-controlled study.
    Bogaty P, Brophy JM, Noel M, Boyer L, Simard S, Bertrand F, Dagenais GR.
    Circulation; 2004 Aug 24; 110(8):934-9. PubMed ID: 15302800
    [Abstract] [Full Text] [Related]

  • 2. Divergent effects of rofecoxib on endothelial function and inflammation in acute coronary syndromes.
    Lekakis JP, Vamvakou G, Andreadou I, Ganiatsos G, Karatzis E, Protogerou A, Papaioannou T, Ikonomidis I, Papamichael C, Mavrikakis ME.
    Int J Cardiol; 2006 Oct 10; 112(3):359-66. PubMed ID: 16330117
    [Abstract] [Full Text] [Related]

  • 3. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
    Weir MR, Sperling RS, Reicin A, Gertz BJ.
    Am Heart J; 2003 Oct 10; 146(4):591-604. PubMed ID: 14564311
    [Abstract] [Full Text] [Related]

  • 4. Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension.
    Hermann M, Camici G, Fratton A, Hurlimann D, Tanner FC, Hellermann JP, Fiedler M, Thiery J, Neidhart M, Gay RE, Gay S, Lüscher TF, Ruschitzka F.
    Circulation; 2003 Nov 11; 108(19):2308-11. PubMed ID: 14597594
    [Abstract] [Full Text] [Related]

  • 5. Clinical and biochemical results of the metalloproteinase inhibition with subantimicrobial doses of doxycycline to prevent acute coronary syndromes (MIDAS) pilot trial.
    Brown DL, Desai KK, Vakili BA, Nouneh C, Lee HM, Golub LM.
    Arterioscler Thromb Vasc Biol; 2004 Apr 11; 24(4):733-8. PubMed ID: 14962945
    [Abstract] [Full Text] [Related]

  • 6. A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers.
    Greenberg HE, Gottesdiener K, Huntington M, Wong P, Larson P, Wildonger L, Gillen L, Dorval E, Waldman SA.
    J Clin Pharmacol; 2000 Dec 11; 40(12 Pt 2):1509-15. PubMed ID: 11185674
    [Abstract] [Full Text] [Related]

  • 7. High-dose statin and COX-2 inhibitor therapy rapidly decreases C-reactive protein level in patients with unstable angina.
    Chyrchel M, Dudek D, Bartuś S, Legutko J, Heba G, Dubiel JS.
    Kardiol Pol; 2004 Sep 11; 61(9):213-21; discussion 222-4. PubMed ID: 15531933
    [Abstract] [Full Text] [Related]

  • 8. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.
    Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA, Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators.
    N Engl J Med; 2005 Mar 17; 352(11):1092-102. PubMed ID: 15713943
    [Abstract] [Full Text] [Related]

  • 9. Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. Rofecoxib Osteoarthritis Pilot Study Group.
    Ehrich EW, Schnitzer TJ, McIlwain H, Levy R, Wolfe F, Weisman M, Zeng Q, Morrison B, Bolognese J, Seidenberg B, Gertz BJ.
    J Rheumatol; 1999 Nov 17; 26(11):2438-47. PubMed ID: 10555907
    [Abstract] [Full Text] [Related]

  • 10. Effects of selective and non-selective cyclo-oxygenase inhibition on endothelial function in patients with rheumatoid arthritis.
    Wong M, Jiang BY, McNeill K, Farish S, Kirkham B, Chowienczyk P.
    Scand J Rheumatol; 2007 Nov 17; 36(4):265-9. PubMed ID: 17763203
    [Abstract] [Full Text] [Related]

  • 11. A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients.
    Higuchi T, Iwama T, Yoshinaga K, Toyooka M, Taketo MM, Sugihara K.
    Clin Cancer Res; 2003 Oct 15; 9(13):4756-60. PubMed ID: 14581346
    [Abstract] [Full Text] [Related]

  • 12. Selective COX-2 inhibition with different doses of rofecoxib does not impair endothelial function in patients with coronary artery disease.
    Tikiz C, Utük O, Bayturan O, Bayindir P, Ekmekçi C, Tikiz H.
    Acta Med Okayama; 2005 Feb 15; 59(1):11-7. PubMed ID: 15902994
    [Abstract] [Full Text] [Related]

  • 13. Rofecoxib regulates the expression of genes related to the matrix metalloproteinase pathway in humans: implication for the adverse effects of cyclooxygenase-2 inhibitors.
    Wang XM, Wu TX, Lee YS, Dionne RA.
    Clin Pharmacol Ther; 2006 Apr 15; 79(4):303-15. PubMed ID: 16580899
    [Abstract] [Full Text] [Related]

  • 14. Cyclooxygenase-2 inhibition by rofecoxib reverses naturally occurring fever in humans.
    Schwartz JI, Chan CC, Mukhopadhyay S, McBride KJ, Jones TM, Adcock S, Moritz C, Hedges J, Grasing K, Dobratz D, Cohen RA, Davidson MH, Bachmann KA, Gertz BJ.
    Clin Pharmacol Ther; 1999 Jun 15; 65(6):653-60. PubMed ID: 10391671
    [Abstract] [Full Text] [Related]

  • 15. Low dose rofecoxib, inflammation and prostacyclin synthesis in acute coronary syndromes.
    Kuklińska AM, Musiał WJ, Kamiński KA, Kralisz P, Modrzejewski W, Sobkowicz B, Dobrzycki S, Stec S, Wojtkowska I.
    Rocz Akad Med Bialymst; 2005 Jun 15; 50():339-42. PubMed ID: 16358997
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of rofecoxib in patients with chronic low back pain: results from two 4-week, randomized, placebo-controlled, parallel-group, double-blind trials.
    Katz N, Ju WD, Krupa DA, Sperling RS, Bozalis Rodgers D, Gertz BJ, Gimbel J, Coleman S, Fisher C, Nabizadeh S, Borenstein D, Vioxx Chronic Low Back Pain Study Group.
    Spine (Phila Pa 1976); 2003 May 01; 28(9):851-8; discussion 859. PubMed ID: 12941996
    [Abstract] [Full Text] [Related]

  • 17. The new COX-2 inhibitors: rofecoxib (Vioxx) and celecoxib (Celebrex).
    Wynn RL.
    Gen Dent; 2000 May 01; 48(1):16-20. PubMed ID: 11199547
    [No Abstract] [Full Text] [Related]

  • 18. Xuezhikang, an extract of cholestin, protects endothelial function through antiinflammatory and lipid-lowering mechanisms in patients with coronary heart disease.
    Zhao SP, Liu L, Cheng YC, Shishehbor MH, Liu MH, Peng DQ, Li YL.
    Circulation; 2004 Aug 24; 110(8):915-20. PubMed ID: 15313947
    [Abstract] [Full Text] [Related]

  • 19. Analgesic efficacy of the cyclooxygenase-inhibiting nitric oxide donor AZD3582 in postoperative dental pain: Comparison with naproxen and rofecoxib in two randomized, double-blind, placebo-controlled studies.
    Michael Hill C, Sindet-Pederson S, Seymour RA, Hawkesford JE, Coulthard P, Lamey PJ, Gerry Cowan C, Wickens M, Jeppsson L, Dean AD, Svensson O.
    Clin Ther; 2006 Sep 24; 28(9):1279-95. PubMed ID: 17062301
    [Abstract] [Full Text] [Related]

  • 20. The trade-off between cardiovascular and gastrointestinal effects of rofecoxib.
    Florentinus SR, Heerdink ER, de Boer A, van Dijk L, Leufkens HG.
    Pharmacoepidemiol Drug Saf; 2005 Jul 24; 14(7):437-41. PubMed ID: 15937867
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.